A drug that physically brings immune T cells into contact with cancer cells has delivered a large survival gain in a Phase III small-cell lung cancer trial. In DeLLphi-305, tarlatamab plus durvalumab extended median overall survival to 21.1 months, compared with 12.7 months for durvalumab alone.
The finding is notable because extensive-stage small-cell lung cancer is aggressive and frequently returns quickly after chemotherapy. It is also more specific than the headline “first-line treatment” may suggest: patients first received platinum chemotherapy, etoposide and durvalumab, and only those whose disease had not progressed entered the maintenance comparison.
A bridge between T cells and tumour cells
Tarlatamab, sold in the United States as Imdelltra for previously treated disease, is a bispecific T-cell engager. One end binds DLL3, a protein found at high levels on many small-cell lung cancer cells. The other binds CD3 on T cells. That molecular bridge pulls immune cells close enough to attack the tumour.
Durvalumab, sold as Imfinzi, is a checkpoint inhibitor. It blocks PD-L1, another mechanism cancers use to dampen immune responses. The combination therefore tries to recruit T cells and keep them active after initial chemotherapy has reduced the tumour burden.
The survival signal was unusually clear
The randomised study enrolled 563 patients. At roughly 16 months of median follow-up, the combination reduced the risk of death by 58%, with a hazard ratio of 0.42. Nearly 80% of patients receiving both drugs were alive at one year, versus 53% receiving durvalumab alone. Median progression-free survival was 7.4 months compared with 1.9 months, and the objective response rate was 26.4% versus 4.1%.
Those figures come from Amgen’s 24 October results announcement. The study was simultaneously published in the New England Journal of Medicine, giving clinicians access to the full methods rather than only a conference summary.
A hazard ratio describes relative risk over time; it does not mean 58% of all patients were saved. The median numbers show the observed centre of each survival curve, while longer follow-up will reveal how durable the separation remains.
The safety cost cannot be edited out
Grade 3 or higher treatment-related adverse events occurred in 20.9% of combination patients and 10.8% of those receiving durvalumab alone. Cytokine release syndrome—an inflammatory reaction caused by intense immune activation—occurred in 49.6% of patients receiving tarlatamab. Most cases were grade 1 or 2, one was grade 3, and no grade 4 or higher cases were reported in the release. Early doses required monitoring in a healthcare setting.
That profile makes the result a benefit-risk calculation, not a simple upgrade. Patients in the trial had already responded to or remained stable after induction therapy; the data do not establish the same effect in people whose disease progresses during initial treatment.
What changes next
Tarlatamab already has regulatory history in later-line extensive-stage disease, but the maintenance combination represents a new use and will require regulatory review. Independent reporting confirms the major efficacy and safety figures while noting the drug’s existing narrower approval.
The result matters because it moves a T-cell engager earlier in treatment and shows that two immune mechanisms can be combined after chemotherapy. Regulators must still assess the maintenance indication, dosing and monitoring requirements; a positive Phase III trial does not itself change an approved label. It also does not remove the toxicity, hospital-readiness or access questions that come with the platform.
This article is general information, not medical advice.
Leave a Reply